Growth opportunity Established in 1981 as a leading DNA and RNA manufacturing specialist with a global customer base, ChemGenes shows potential for expanded contract manufacturing partnerships, scale-up collaborations, and custom nucleic acid production services for biotech, pharma, and diagnostics developers.

Facility expansion Recent facility relocation and expansion in Wilmington, Massachusetts indicate capacity growth and readiness to take on larger or additional projects, suggesting opportunities for new service agreements, increased batch throughput, and regional supply chain engagements.

Product breadth Offering the broadest range of modified chemistries and nucleic acid building blocks positions ChemGenes as a strategic supplier for customers needing diverse chemistry options, enabling upsell on advanced nucleic acid synthesis, modified oligos, and bespoke materials for therapeutics and diagnostics.

COVID-19 impact Involvement in manufacturing critical materials for lifesaving vaccines and diagnostics highlights credibility in high-stakes manufacturing, suggesting potential for long-term supply agreements, rapid-response projects, and certifications that appeal to large biopharma buyers.

Mid-market fit Revenue in the mid tens of millions with a relatively small employee base signals agility and personalized service, making ChemGenes an attractive partner for mid-market biotech firms and university programs seeking reliable, responsive nucleic acid supply and kitting services.